Everest Organics Ltd.
Snapshot View

142.05 +11.25 ▲8.6%

27 June 2022, 04:01:00 PM
Volume: 7,570

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.everestorganicsltd.com
Market Cap 113.64 Cr.
Enterprise Value(EV) 151.77 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 1.43 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 99.42 Trailing Twelve Months Ending 2022-03
Industry PE 29.84 Trailing Twelve Months Ending 2022-03
Book Value / Share 58.50 Trailing Twelve Months Ending 2022-03
Price to Book Value 2.43 Calculated using Price: 142.05
Dividend Yield 1.06 Period Ending 2021-03
No. of Shares Subscribed 0.80 Cr. 8,000,000 Shares
FaceValue 10
Company Profile
The company's facilities comply to GMP standards and is certified by the Drug Control Authority of the Government of Andhra Pradesh, India. It supply products to major multinational companies abroad, prominent well established formulation companies in India, Europe, USA, Far East and the Middle East, and also to Latin / Central / South American Countries. The company also provides adequate technical & documentary support for their products and its products comply to various pharmacopial standards like BP, USP, EP and IP Standards as desired by the customer.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+8.60%
1 Week
+8.44%
1 Month
-11.82%
3 Month
-21.78%
6 Month
-43.85%
1 Year
-58.31%
2 Year
-18.48%
5 Year
+36.19%
10 Year
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 25.00 23.31 33.19 3.06 12.25 9.86 33.63 36.22 33.96
Return on Capital Employed (%) 15.43 13.82 15.84 8.90 13.55 13.80 35.30 35.22 33.76
Return on Assets (%) 1.35 1.42 2.50 0.25 1.67 1.90 7.45 9.58 10.73

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 4 4 6 6 16 19 26 34 47 47
Non Curr. Liab. 5 10 11 14 7 8 10 12 11 19
Curr. Liab. 48 51 50 56 63 67 71 74 77 113
Minority Int.
Equity & Liab. 56 65 67 76 86 94 107 120 135 178
Non Curr. Assets 24 25 25 29 37 36 40 41 46 60
Curr. Assets 33 41 42 47 49 58 67 79 89 118
Misc. Exp. not W/O
Total Assets 56 65 67 76 86 94 107 120 135 178

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 80 96 106 99 107 112 156 167 182 200
Other Income 0 1 1 1 1 1 1 1 1 2
Total Income 80 97 107 100 108 113 156 169 183 202
Total Expenditure -74 -91 -98 -94 -101 -105 -138 -148 -159 -194
PBIDT 6 6 8 6 7 8 18 21 24 9
Interest -3 -3 -3 -3 -3 -3 -3 -3 -3 -3
Depreciation -2 -2 -3 -3 -2 -3 -3 -3 -3 -4
Taxation 0 0 0 0 0 -1 -5 -3 -4 -1
Exceptional Items -1 -1
PAT 1 1 2 0 1 2 8 11 14 1
Adjusted EPS 1 1 2 1 2 2 9 14 17 1

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 6 7 1 4 7 10 5 9 10 14
Cash Fr. Inv. -5 -4 -3 -3 -7 -8 -4 -5 -6 -12
Cash Fr. Finan. -2 -3 2 -2 0 -2 0 -3 -3 -2
Net Change 0 0 0 0 0 0 1 1 0 0
Cash & Cash Eqvt 1 1 1 1 1 1 1 2 2 2

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 73.79 73.79 73.79 74.04 74.15 74.15 74.15 74.15 74.15
Public 26.21 26.21 26.21 25.96 25.85 25.85 25.85 25.85 25.85
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 09 Jun 2022
Announcement under Regulation 30 (LODR)-Credit Rating
With reference to the captioned subject and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 we would like to inform you that based on ICRA update the Companys credit rating has been revised.
Wed, 08 Jun 2022
Disclosure Of Related Party Transactions For Half Year Ended 31.03.2022
Pursuant to Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith disclosure on Related Party Transactions for the half year ended March 31 2022 in the requisite format specified under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22 2021.This is for your information and records.
Mon, 30 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
With reference to the audited financial results published on Financial Express (English Newspaper) and in Nava Telangana (Telugu Newspaper) dated 28.05.2022 and as submitted to the BSE on 28.05.2022 the signatory part was corrected from Managing Director to Chief Executive Officer and in Note No. 2 Audited Review Report was corrected as Auditors Report. The copy of corrigendum is enclosed herewith.Kindly take the above information on record.

Technical Scans View Details

Mon, 27 Jun 2022
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Crossing Last Week High Close Crossing Last Week High
Opening at Low Opening at Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 200,572.41 835.95 +1.4%
Divi's Laboratories Ltd. 97,518.56 3,679.05 0.0%
Cipla Ltd. 75,086.75 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. 71,855.08 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. 54,559.09 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. 48,438.53 2,858.25 -0.6%
Gland Pharma Ltd. 43,775.42 2,658.60 +0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 61.29 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2022-03 32.99 3,679.05 0.0%
Cipla Ltd. Consolidated 2022-03 29.83 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.92 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 51.70 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 62.24 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2022-03 36.13 2,658.60 +0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 4.18 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2022-03 8.33 3,679.05 0.0%
Cipla Ltd. Consolidated 2022-03 3.60 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.74 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 9.68 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8.12 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2022-03 6.12 2,658.60 +0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 0.10 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,658.60 +0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 14.13 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,658.60 +0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 14.13 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,658.60 +0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,658.60 +0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,658.60 +0.6%

FAQ's On Everest Organics Ltd.

Can I Buy Everest Organics Shares now?

What is the Share Price of Everest Organics?

What is the Relative Strength Index (RSI) Value of Everest Organics?

What is the Market Capital (MCAP) of Everest Organics?

What are the key metrics to analyse Everest Organics?

What is the Price Performance of Everest Organics?